1. Home
  2. NYC vs HBIO Comparison

NYC vs HBIO Comparison

Compare NYC & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Strategic Investment Co.

NYC

American Strategic Investment Co.

N/A

Current Price

$8.36

Market Cap

24.8M

Sector

Finance

ML Signal

N/A

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

HOLD

Current Price

$6.24

Market Cap

26.5M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NYC
HBIO
Founded
2013
1901
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Laboratory Analytical Instruments
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
24.8M
26.5M
IPO Year
2014
2000

Fundamental Metrics

Financial Performance
Metric
NYC
HBIO
Price
$8.36
$6.24
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$18.00
AVG Volume (30 Days)
51.6K
15.6K
Earning Date
04-15-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
85.28
N/A
EPS
N/A
N/A
Revenue
N/A
$116,176,000.00
Revenue This Year
$56.73
$4.77
Revenue Next Year
N/A
$8.55
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.00
$0.38
52 Week High
$14.73
$7.50

Technical Indicators

Market Signals
Indicator
NYC
HBIO
Relative Strength Index (RSI) 47.14 52.21
Support Level $8.19 $5.91
Resistance Level $8.63 $6.69
Average True Range (ATR) 0.70 0.29
MACD -0.01 0.01
Stochastic Oscillator 36.32 43.89

Price Performance

Historical Comparison
NYC
HBIO

About NYC American Strategic Investment Co.

American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

Share on Social Networks: